EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Factors Associated With Biologic Therapy After Ileal Pouch–Anal Anastomosis in Patients With Ulcerative Colitis

Maya Fischman iD, Lihi Godny iD, Adi Friedenberg, Revital Barkan, Ian White, Nir Wasserberg, Keren Rabinowitz, Irit Avni-Biron, Hagar Banai, Yifat Snir, Yelena Broitman, Henit Yanai iD und 2 weitere

Inflammatory Bowel Diseases · 07.07.2025 · 31 (7) · 1934-1942

DOI: 10.1093/ibd/izae272 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 14.11.2024. Verfasst von Maya Fischman und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Proctocolectomy, Restorative, Biological Therapy, Colonic Pouches. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: The Leona M. and Harry B. Helmsley Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with ulcerative colitis (UC) undergoing proctocolectomy and ileal pouch–anal anastomosis (IPAA) may eventually require biologic therapy. Factors associated with biologic therapy after IPAA have not been previously studied.

Methods

All patients with UC after total proctocolectomy and IPAA who were followed at Rabin Medical Center comprehensive pouch clinic and who consented to prospective observational follow-up were included. The primary outcome was the initiation of biologic therapy after IPAA. Cox proportional hazard models were used to evaluate potential associations.

Results

Out of 400 patients receiving their care at the pouch clinic, 148 patients consented to prospective observational follow-up and constituted the study cohort. The median age at diagnosis was 21 years and the age at IPAA was 30 years. Median time-to-biologic therapy initiation post-IPAA was 9.2 years, with 34 patients (23%) initiating biologic therapy: Associated factors for initiating biologic therapy post-IPAA were preoperative treatment with biologic therapy and immunomodulatory therapy (hazard ratio [HR] 6.1 and 3.6, respectively, P < .001); Arab descent (HR 5.3, P < .001); heterozygosity of NOD2 variant rs2066845 (HR 5.1, P = .03); past smoking status (HR 2.3, P = .03); 3-stage IPAA (HR 2.3, P = .02); immediate postoperative complications (HR 2.1, P = .033); and pediatric-onset UC (HR 2.1, P = .03). None of the patients undergoing IPAA due to dysplasia (n = 27) required biologic therapy.

Conclusions

Several demographic, disease-related, surgery-related, and genetic factors associated with post-IPAA biologic therapy were identified. Physicians treating patients with UC undergoing colectomy should incorporate these factors into their decision-making process. These patients may benefit from closer postoperative follow-up, and earlier initiation of biologic therapy should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeProctocolectomy, RestorativeBiological TherapyColonic PouchesHumansFemaleMaleAdultProspective StudiesYoung AdultFollow-Up StudiesAdolescentMiddle AgedChildPostoperative ComplicationsProportional Hazards Models

Stichwörter der Autor:innen

antibiotic-refractory pouchitisbiologicschronic pouchitispouchitisrisk factors

Autor:innen und Institutionen

  • Department of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel.
  • Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Division of Surgery, Rabin Medical Center, Petah-Tikva, Israel.
  • Felsenstein Medical Research Center, Rabin Medical Center, Tel Aviv University, Petah-Tikva, Israel.

ORCID-Profile: Maya Fischman, Lihi Godny, Henit Yanai, Jacob E Ollech

Förderung

  • The Leona M. and Harry B. Helmsley Charitable Trust

Zitieren

APA

Fischman, M., Godny, L., Friedenberg, A., Barkan, R., White, I., Wasserberg, N., Rabinowitz, K., Avni-Biron, I., Banai, H., Snir, Y., Broitman, Y., Yanai, H., Dotan, I., & Ollech, J. E. (2025). Factors Associated With Biologic Therapy After Ileal Pouch–Anal Anastomosis in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases, 31(7), 1934-1942. https://doi.org/10.1093/ibd/izae272

Vancouver

Fischman M, Godny L, Friedenberg A, Barkan R, White I, Wasserberg N, et al. Factors Associated With Biologic Therapy After Ileal Pouch–Anal Anastomosis in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases. 2025;31(7):1934-1942. doi:10.1093/ibd/izae272

BibTeX
@article{Fischman2025,
  author = {Fischman, Maya and Godny, Lihi and Friedenberg, Adi and Barkan, Revital and White, Ian and Wasserberg, Nir and Rabinowitz, Keren and Avni-Biron, Irit and Banai, Hagar and Snir, Yifat and Broitman, Yelena and Yanai, Henit and Dotan, Iris and Ollech, Jacob E},
  title = {Factors Associated With Biologic Therapy After Ileal Pouch–Anal Anastomosis in Patients With Ulcerative Colitis},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {7},
  pages = {1934--1942},
  doi = {10.1093/ibd/izae272}
}
Kostenlos starten →